Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the cintredekin besudotox intraparenchymal study group

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 837-844

  Kunwar, Sandeep ^a   Prados, Michael D ^a   Chang, Susan M ^a   Berger, Mitchel S ^a   Lang, Frederick F ^a   Piepmeier, Joseph M ^a   Sampson, John H ^a   Ram, Zvi ^a   Gutin, Philip H ^a   Gibbons, Robert D ^a   Aldape, Kenneth D ^a   Croteau, David J ^a   Sherman, Jeffrey W ^a   Puri, Raj K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINTREDEKIN BESUDOTOX; INTERLEUKIN 13; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; EXOTOXIN; IL13 PE38QQR; IL13-PE38QQR; IMMUNOTOXIN;

ADULT; AGED; APHASIA; ARTICLE; ASTHENIA; CANCER SURGERY; CATHETER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; CRANIOTOMY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FACIAL NERVE PARALYSIS; FEMALE; FOLLOW UP; GAIT DISORDER; GLIOBLASTOMA; HEMIPARESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOTOR NEURON DISEASE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SPEECH DISORDER; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; BRAIN TUMOR; CATHETERIZATION; DRUG DELIVERY SYSTEM; GLIOMA; METHODOLOGY; MIDDLE AGED; MORTALITY; THERMODYNAMICS; TUMOR RECURRENCE;

ADULT; AGED; CATHETERIZATION; CONVECTION; DRUG DELIVERY SYSTEMS; EXOTOXINS; FEMALE; GLIOMA; HUMANS; IMMUNOTOXINS; INTERLEUKIN-13; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SUPRATENTORIAL NEOPLASMS; TISSUE DISTRIBUTION;

EID: 33947547455     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.1117     Document Type: Article

References (31)

1. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
2. Watanabe M, Tanaka R, Takeda N: Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 34:463-469, 1992
3. Wilson CB: Glioblastoma: The past, the present and the future, in Clinical Neurosurgery. Baltimore, MD, Williams & Wilkins, 1992, pp 32-48
4. Yung W, Prados M, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
5. Yung W, Albright R, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
6. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
7. Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-Brain Tumor Treatment Group. Lancet 345:1008-1012, 1995
8. Westphal M, Hilt DC, Bortey E, et al: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 5:79-88, 2003
9. Debinski W, Obiri NI, Powers SK, et al: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1:1253-1258, 1995
10. Debinski W, Gibo DM, Hulet SW, et al: Receptor for interleukin 13 is a marker and therapeutic target for human high grade gliomas. Clin Cancer Res 5:985-990, 1999
11. Joshi BH, Plautz GE, Puri RK: Interleukin-13 receptor α chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60:1168-1172, 2000
12. Liu H, Jacobs BS, Liu J, et al: Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: Non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother 49:319-324, 2000
13. Husain SR, Puri RK: Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: From bench to bedside. J Neurooncol 65:37-48, 2003
14. Kawakami M, Kawakami K, Puri RK: Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 1:999-1007, 2000
15. Kunwar S, Pai L, Pastan I: Cytotoxicity and antitumor effects of growth factor-toxin fusions proteins on human glioblastoma multiforme cells. J Neurosurg 79:569-576, 1993
16. Husain SR, Joshi BH, Puri RK: Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92(2):168-175, 2001
17. Morrison PF, Laske DW, Bobo H, et al: High-flow microinfusion: Tissue penetration and pharmacodynamics. Am J Physiol 266:R292-R305, 1994
18. Bobo RH, Laske DW, Akbasak A, et al: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076-2080, 1994
19. Lieberman DM, Laske DW, Morrison PF, et al: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:1021-1029, 1995
20. Laske DW, Morrison PF, Lieberman DM, et al: Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 87:586-594, 1997
21. Chen MY, Lonser RR, Morrison PF, et al: Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90:315-320, 1999
22. Morrison PF, Chen MY, Chadwick RS, et al: Focal delivery during direct infusion to brain: Role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol 277:1218-1229, 1999
23. Kaiser MG, Parsa AT, Fine RL, et al: Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47:1391-1398, 2000
24. Kunwar S: Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim results from ongoing phase I studies, in Ram Z (ed): Local Therapies for Glioma: Present Status and Future Developments. New York, NY, Sprienger Wein, 2003, pp 105-111
25. Weaver M, Laske DW: Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65:3-13, 2003
26. Weber F, Asher A, Bucholz R, et al: Safety, tolerability, and tumor response of IL-4 pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125-137, 2003
27. Sampson JH, Akabani GE, Archer GE, et al: Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-a and a mutated form of the pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumor. J Neurooncol 65:37-48, 2003
28. Lidar Z, Mardor Y, Jonas T, et al: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 100:472-479, 2004
29. Patel SJ, Shapiro WR, Laske DW, et al: Safety and feasibility of convection-enhanced delivery of cotara for treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 56:1243-1252, 2004
30. Parney I, Kunwar S, McDermott M, et al: Neuroradiographic changes following convection-enhanced delivery of the conjugated toxin IL13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-275, 2005
31. Bauman MA, Gillies GT, Raghavan R, et al: Physical characterization of neurocatheter performance in a brain phantom gelatin with nanoscale porosity: Steady-state and oscillatory flows. Nanotechnology 15:92-97, 2004